Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions
JAZZ Stock Forecast
Jazz Pharmaceuticals stock forecast is as follows: an average price target of $200.00 (represents a 83.84% upside from JAZZ’s last price of $108.79) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
JAZZ Price Target
The average price target for Jazz Pharmaceuticals (JAZZ) is $200.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $250.00 to $169.00. This represents a potential 83.84% upside from JAZZ's last price of $108.79.
JAZZ Analyst Ratings
According to 6 Wall Street analysts, Jazz Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for JAZZ stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Jazz Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Annabel Samimy | Stifel Nicolaus | $230.00 | $105.22 | 118.59% | 111.42% |
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $169.00 | $104.48 | 61.75% | 55.35% |
| May 02, 2024 | Daniel Busb | RBC Capital | $176.00 | $110.31 | 59.55% | 61.78% |
| Mar 20, 2024 | David Amsellem | Piper Sandler | $188.00 | $124.79 | 50.65% | 72.81% |
| Dec 09, 2022 | - | Goldman Sachs | $190.00 | $150.07 | 26.61% | 74.65% |
| Nov 10, 2022 | - | Goldman Sachs | $192.00 | $149.90 | 28.09% | 76.49% |
| Nov 10, 2022 | - | RBC Capital | $207.00 | $149.90 | 38.09% | 90.27% |
| Jun 20, 2022 | David Amsellem | Piper Sandler | $193.00 | $142.91 | 35.05% | 77.41% |
| Jun 13, 2022 | Ashwani Verma | UBS | $194.00 | $141.59 | 37.02% | 78.33% |
| Mar 03, 2022 | Ami Fadia | Needham | $215.00 | $152.90 | 40.61% | 97.63% |
The latest Jazz Pharmaceuticals stock forecast, released on Sep 11, 2024 by Annabel Samimy from Stifel Nicolaus, set a price target of $230.00, which represents a 118.59% increase from the stock price at the time of the forecast ($105.22), and a 111.42% increase from JAZZ last price ($108.79).
Jazz Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 4 |
| Avg Price Target | $230.00 | $230.00 | $190.75 |
| Last Closing Price | $108.79 | $108.79 | $108.79 |
| Upside/Downside | 111.42% | 111.42% | 75.34% |
In the current month, the average price target of Jazz Pharmaceuticals stock is $230.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 111.42% increase as opposed to Jazz Pharmaceuticals's last price of $108.79. This month's average price target is down 0.00% compared to last quarter, and up 20.58% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 09, 2024 | UBS | Underperform | Underperform | Hold |
| Aug 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 01, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 02, 2024 | UBS | Buy | Buy | Hold |
| Jun 06, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 05, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jun 05, 2024 | Needham | Underperform | Underperform | Hold |
| May 29, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 02, 2024 | UBS | Buy | Buy | Hold |
Jazz Pharmaceuticals's last stock rating was published by Wells Fargo on Sep 09, 2024. The company gave JAZZ a "Buy" rating, the same as its previous rate.
Jazz Pharmaceuticals Financial Forecast
Jazz Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $957.32M | $892.81M | $972.12M | $940.65M | - | $813.72M | $896.73M | $838.12M | $751.81M | $607.58M | $665.52M | $600.89M | $562.44M | $534.73M | $581.74M | $537.70M | $534.13M | $508.19M | $476.46M | $469.37M |
| Avg Forecast | $1.15B | $1.10B | $1.06B | $996.27M | $1.07B | $1.04B | $1.01B | $953.97M | $1.01B | $968.41M | $941.99M | $897.39M | $975.48M | $939.98M | $902.49M | $852.45M | $864.30M | $832.01M | $731.89M | $609.32M | $638.84M | $577.62M | $503.21M | $544.56M | $560.55M | $523.89M | $508.25M | $465.93M | $395.30M | $435.28M |
| High Forecast | $1.17B | $1.12B | $1.09B | $1.02B | $1.10B | $1.06B | $1.03B | $975.12M | $1.07B | $989.88M | $962.87M | $917.29M | $997.11M | $960.82M | $902.49M | $883.59M | $895.87M | $862.41M | $758.63M | $631.58M | $662.18M | $598.73M | $521.60M | $564.46M | $581.02M | $543.03M | $526.82M | $482.95M | $474.36M | $522.34M |
| Low Forecast | $1.12B | $1.07B | $1.04B | $969.55M | $1.05B | $1.01B | $982.88M | $928.38M | $957.26M | $942.43M | $916.72M | $873.32M | $949.31M | $914.76M | $902.49M | $820.55M | $831.96M | $800.88M | $704.51M | $586.52M | $614.94M | $556.01M | $484.38M | $524.18M | $539.57M | $504.29M | $489.24M | $448.49M | $316.24M | $348.23M |
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.02% | 0.99% | 1.00% | 1.00% | - | 0.95% | 1.04% | 1.01% | 1.03% | 1.00% | 1.04% | 1.04% | 1.12% | 0.98% | 1.04% | 1.03% | 1.05% | 1.09% | 1.21% | 1.08% |
Jazz Pharmaceuticals's average Quarter revenue forecast for Sep 23 based on 9 analysts is $968.41M, with a low forecast of $942.43M, and a high forecast of $989.88M. JAZZ's average Quarter revenue forecast represents a 1.16% increase compared to the company's last Quarter revenue of $957.32M (Jun 23).
Jazz Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $157.64M | $276.84M | $249.00M | $307.24M | - | $267.26M | $205.40M | $190.06M | $82.04M | $240.20M | $243.43M | $266.44M | $263.48M | $-123.25M | $235.66M | $197.89M | $266.41M | $192.66M | $232.93M | $238.48M |
| Avg Forecast | $404.04M | $387.82M | $374.83M | $351.12M | $378.77M | $365.24M | $355.94M | $314.37M | $354.77M | $341.30M | $331.99M | $285.79M | $343.79M | $125.44M | $318.07M | $259.81M | $304.61M | $114.04M | $71.64M | $226.60M | $255.02M | $251.42M | $212.65M | $-163.72M | $218.50M | $170.41M | $230.59M | $161.57M | $185.12M | $219.80M |
| High Forecast | $413.00M | $396.42M | $383.14M | $358.90M | $387.17M | $372.27M | $363.84M | $377.25M | $375.84M | $348.87M | $339.35M | $342.95M | $351.41M | $150.53M | $318.07M | $311.78M | $315.73M | $136.84M | $85.97M | $271.92M | $306.02M | $301.70M | $255.18M | $-130.98M | $262.20M | $204.49M | $276.71M | $193.88M | $222.14M | $263.76M |
| Low Forecast | $393.21M | $377.42M | $364.77M | $341.70M | $368.61M | $354.71M | $346.40M | $251.50M | $337.37M | $332.14M | $323.08M | $228.64M | $334.57M | $100.35M | $318.07M | $207.85M | $293.21M | $91.23M | $57.32M | $181.28M | $204.01M | $201.14M | $170.12M | $-196.46M | $174.80M | $136.33M | $184.47M | $129.25M | $148.09M | $175.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.47% | 0.97% | 0.72% | 2.45% | - | 1.03% | 0.67% | 1.67% | 1.15% | 1.06% | 0.95% | 1.06% | 1.24% | 0.75% | 1.08% | 1.16% | 1.16% | 1.19% | 1.26% | 1.08% |
9 analysts predict JAZZ's average Quarter EBITDA for Sep 23 to be $341.30M, with a high of $348.87M and a low of $332.14M. This is 116.51% upper than Jazz Pharmaceuticals's previous annual EBITDA (Jun 23) of $157.64M.
Jazz Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $104.44M | $69.42M | $-239.95M | $-17.10M | - | $5.79M | $-32.36M | $-52.83M | $-363.32M | $121.83M | $133.41M | $148.23M | $114.80M | $-157.83M | $73.99M | $102.28M | $261.90M | $85.20M | $159.47M | $149.32M |
| Avg Forecast | $412.04M | $396.58M | $360.77M | $301.94M | $421.87M | $385.44M | $342.70M | $2.05M | $360.99M | $343.42M | $309.51M | $1.86M | $61.47M | $-34.87M | $261.30M | $1.69M | $252.98M | $-31.70M | $-317.28M | $114.94M | $139.77M | $139.88M | $92.65M | $-209.66M | $68.60M | $88.07M | $226.68M | $71.45M | $126.73M | $137.62M |
| High Forecast | $423.92M | $408.02M | $371.17M | $310.64M | $434.03M | $416.33M | $352.58M | $2.46M | $385.69M | $353.32M | $318.43M | $2.24M | $63.24M | $-27.90M | $261.30M | $2.03M | $264.99M | $-25.36M | $-253.82M | $137.92M | $167.72M | $167.85M | $111.18M | $-167.73M | $82.33M | $105.69M | $272.02M | $85.74M | $152.08M | $165.15M |
| Low Forecast | $397.67M | $382.76M | $348.19M | $291.41M | $407.16M | $346.12M | $330.75M | $1.64M | $336.28M | $331.45M | $298.72M | $1.49M | $59.33M | $-41.84M | $261.30M | $1.36M | $240.67M | $-38.04M | $-380.74M | $91.95M | $111.81M | $111.90M | $74.12M | $-251.59M | $54.88M | $70.46M | $181.35M | $57.16M | $101.38M | $110.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.34% | 37.25% | -3.90% | 0.49% | - | 3.42% | -0.13% | 1.67% | 1.15% | 1.06% | 0.95% | 1.06% | 1.24% | 0.75% | 1.08% | 1.16% | 1.16% | 1.19% | 1.26% | 1.08% |
Jazz Pharmaceuticals's average Quarter net income forecast for Sep 23 is $343.42M, with a range of $331.45M to $353.32M. JAZZ's average Quarter net income forecast represents a 228.83% increase compared to the company's last Quarter net income of $104.44M (Jun 23).
Jazz Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $340.84M | $297.92M | $383.20M | $358.48M | - | $308.81M | $398.46M | $363.68M | $429.03M | $260.51M | $247.17M | $207.25M | $191.41M | $208.40M | $214.28M | $178.71M | $176.01M | $167.95M | $161.87M | $155.87M |
| Avg Forecast | $434.02M | $416.60M | $402.63M | $377.17M | $406.88M | $392.34M | $382.35M | $384.37M | $381.09M | $366.62M | $356.62M | $349.43M | $369.29M | $240.03M | $341.66M | $317.66M | $327.20M | $218.21M | $374.67M | $245.76M | $258.94M | $195.57M | $154.48M | $276.83M | $198.67M | $153.89M | $152.35M | $140.84M | $128.63M | $143.67M |
| High Forecast | $443.64M | $425.83M | $411.56M | $385.53M | $415.90M | $399.89M | $390.83M | $461.24M | $403.73M | $374.75M | $364.52M | $419.31M | $377.48M | $288.04M | $341.66M | $381.19M | $339.16M | $261.85M | $449.60M | $294.91M | $310.73M | $234.69M | $185.37M | $332.20M | $238.41M | $184.66M | $182.82M | $169.01M | $154.36M | $172.40M |
| Low Forecast | $422.38M | $405.42M | $391.83M | $367.05M | $395.96M | $381.03M | $372.10M | $307.49M | $362.40M | $356.78M | $347.05M | $279.54M | $359.39M | $192.02M | $341.66M | $254.13M | $314.96M | $174.57M | $299.73M | $196.61M | $207.15M | $156.46M | $123.58M | $221.46M | $158.94M | $123.11M | $121.88M | $112.67M | $102.91M | $114.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.85% | 1.04% | 1.49% | - | 0.97% | 1.22% | 1.67% | 1.15% | 1.06% | 0.95% | 1.06% | 1.24% | 0.75% | 1.08% | 1.16% | 1.16% | 1.19% | 1.26% | 1.08% |
Jazz Pharmaceuticals's average Quarter SG&A projection for Sep 23 is $366.62M, based on 9 Wall Street analysts, with a range of $356.78M to $374.75M. The forecast indicates a 7.56% rise compared to JAZZ last annual SG&A of $340.84M (Jun 23).
Jazz Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 6 | 6 | 7 | 14 | 7 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | $1.63 | $1.09 | $-3.81 | $-0.27 | - | $0.09 | $-0.53 | $-0.86 | $-6.11 | $2.16 | $2.39 | $2.67 | $2.07 | $-2.82 | $1.31 | $1.80 | $4.62 | $1.49 | $2.69 | $2.47 |
| Avg Forecast | $5.92 | $5.70 | $5.18 | $4.34 | $6.06 | $5.54 | $4.92 | $4.18 | $5.18 | $4.93 | $4.45 | $4.24 | $0.88 | $4.66 | $4.18 | $3.84 | $3.63 | $3.32 | $3.52 | $3.73 | $4.24 | $4.08 | $3.11 | $0.64 | $4.12 | $3.60 | $3.58 | $3.16 | $2.40 | $3.06 |
| High Forecast | $6.09 | $5.86 | $5.33 | $4.46 | $6.23 | $5.98 | $5.06 | $4.30 | $5.54 | $5.07 | $4.57 | $4.36 | $0.91 | $4.79 | $4.18 | $4.02 | $3.80 | $3.48 | $3.68 | $3.91 | $4.44 | $4.27 | $3.26 | $0.67 | $4.32 | $3.77 | $3.75 | $3.31 | $2.88 | $3.67 |
| Low Forecast | $5.71 | $5.50 | $5.00 | $4.19 | $5.85 | $4.97 | $4.75 | $4.03 | $4.83 | $4.76 | $4.29 | $4.09 | $0.85 | $4.50 | $4.18 | $3.65 | $3.45 | $3.16 | $3.35 | $3.55 | $4.03 | $3.88 | $2.96 | $0.61 | $3.92 | $3.42 | $3.41 | $3.01 | $1.92 | $2.45 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.37% | 0.26% | -4.32% | -0.06% | - | 0.02% | -0.15% | -0.26% | -1.74% | 0.58% | 0.56% | 0.66% | 0.67% | -4.42% | 0.32% | 0.50% | 1.29% | 0.47% | 1.12% | 0.81% |
According to 9 Wall Street analysts, Jazz Pharmaceuticals's projected average Quarter EPS for Sep 23 is $4.93, with a low estimate of $4.76 and a high estimate of $5.07. This represents a 202.60% increase compared to JAZZ previous annual EPS of $1.63 (Jun 23).
Jazz Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| JAZZ | Jazz Pharmaceuticals | $108.79 | $200.00 | 83.84% | Buy |
| LQDA | Liquidia | $9.80 | $17.17 | 75.20% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| TECH | Bio-Techne | $74.67 | $99.21 | 32.86% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| DNLI | Denali Therapeutics | $30.77 | $40.00 | 30.00% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
| HALO | Halozyme Therapeutics | $62.30 | $56.86 | -8.73% | Buy |
| ARGX | argenx SE | $538.01 | $446.55 | -17.00% | Buy |
JAZZ Forecast FAQ
Is Jazz Pharmaceuticals a good buy?
Yes, according to 6 Wall Street analysts, Jazz Pharmaceuticals (JAZZ) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of JAZZ's total ratings.
What is JAZZ's price target?
Jazz Pharmaceuticals (JAZZ) average price target is $200 with a range of $169 to $250, implying a 83.84% from its last price of $108.79. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Jazz Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for JAZZ stock, the company can go up by 83.84% (from the last price of $108.79 to the average price target of $200), up by 129.80% based on the highest stock price target, and up by 55.35% based on the lowest stock price target.
Can Jazz Pharmaceuticals stock reach $200?
JAZZ's highest twelve months analyst stock price target of $250 supports the claim that Jazz Pharmaceuticals can reach $200 in the near future.
What is Jazz Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $230 price target for Jazz Pharmaceuticals (JAZZ) this month, up 111.42% from its last price of $108.79. Compared to the last 3 and 12 months, the average price target increased by 111.42% and increased by 75.34%, respectively.
What are Jazz Pharmaceuticals's analysts' financial forecasts?
Jazz Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.08B (high $4.16B, low $3.96B), average EBITDA is $1.41B (high $1.5B, low $1.32B), average net income is $1.15B (high $1.21B, low $1.09B), average SG&A $1.57B (high $1.67B, low $1.46B), and average EPS is $20.7 (high $21.58, low $19.6). JAZZ's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.31B (high $4.4B, low $4.19B), average EBITDA is $1.52B (high $1.55B, low $1.48B), average net income is $1.47B (high $1.51B, low $1.42B), average SG&A $1.63B (high $1.67B, low $1.59B), and average EPS is $21.13 (high $21.74, low $20.4).
Did the JAZZ's actual financial results beat the analysts' financial forecasts?
Based on Jazz Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $3.66B, which missed the average analysts forecast of $3.67B by -0.30%. Apple's EBITDA was $1.11B, beating the average prediction of $1.05B by 6.14%. The company's net income was $-214M, missing the average estimation of $289.59M by -173.94%. Apple's SG&A was $1.42B, beating the average forecast of $1.27B by 11.69%. Lastly, the company's EPS was $-3.42, missing the average prediction of $13.56 by -125.22%. In terms of the last quarterly report (Jun 2023), Jazz Pharmaceuticals's revenue was $957.32M, beating the average analysts' forecast of $941.99M by 1.63%. The company's EBITDA was $157.64M, missing the average prediction of $331.99M by -52.52%. Jazz Pharmaceuticals's net income was $104.44M, missing the average estimation of $309.51M by -66.26%. The company's SG&A was $340.84M, missing the average forecast of $356.62M by -4.42%. Lastly, the company's EPS was $1.63, missing the average prediction of $4.45 by -63.33%